Beovu

Beovu (brolucizumab) is an intravitreal injection used to treat wet age-related macular degeneration (AMD). This medication helps slow vision loss by targeting vascular endothelial growth factor (VEGF).

Beovu is primarily used for the treatment of wet age-related macular degeneration, a condition characterized by abnormal blood vessel growth in the retina. This medication works by inhibiting vascular endothelial growth factor (VEGF), which can help reduce fluid leakage and slow vision loss. Patients often wonder, 'What is Beovu used for?' and the answer is that it is specifically designed to manage wet AMD, a leading cause of vision impairment in older adults.

Common effects of Beovu may include eye redness, eye pain, and floaters. Some patients may also experience increased eye pressure or inflammation. These effects are generally mild and temporary, but any persistent or severe symptoms should be discussed with a healthcare provider.

Beovu should be administered by a healthcare professional experienced in intravitreal injections. Patients should inform their doctor about any existing eye conditions or allergies before treatment. Proper hygiene and sterile techniques are crucial to minimize the risk of infection.

Beovu may interact with other medications, particularly those that affect the eyes or immune system. Patients should inform their healthcare provider about all current medications, including over-the-counter drugs and supplements. Alcohol and certain foods may also interact with Beovu, so it's important to follow medical advice regarding lifestyle adjustments.